Канал: HIVVaccineEnterprise

ePanel: HIV Antibody Functions Beyond Neutralization

ePanel: HIV Antibody Functions Beyond Neutralization

F9, a new class of antibodies that neutralizes autologous tier 2 viruses in NHP

F9, a new class of antibodies that neutralizes autologous tier 2 viruses in NHP

B cell clonal dynamics during sequential immunizations

B cell clonal dynamics during sequential immunizations

Sequential immunizations with an Integrase defective lentiviral vector

Sequential immunizations with an Integrase defective lentiviral vector

Antiretroviral treatment of acute HIV infection and the prospect for a functional cure

Antiretroviral treatment of acute HIV infection and the prospect for a functional cure

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

“Individualized profiling of germline antibody V genes”

“Individualized profiling of germline antibody V genes”

“Broadly neutralizing antibodies development: Lessons from the Protocol C cohort”

“Broadly neutralizing antibodies development: Lessons from the Protocol C cohort”

ePanel Discussion: HIV Vaccines: Paths to Efficacy

ePanel Discussion: HIV Vaccines: Paths to Efficacy

Margaret Ackerman: Profiling protective antibody responses

Margaret Ackerman: Profiling protective antibody responses

Michael Farzan: AAV-expressed eCD4-Ig as an HIV-1 vaccine alternative

Michael Farzan: AAV-expressed eCD4-Ig as an HIV-1 vaccine alternative

Giuseppe Pantaleo: Novel therapeutic interventions in the targeting of the HIV cell reservoir

Giuseppe Pantaleo: Novel therapeutic interventions in the targeting of the HIV cell reservoir

Georgia Tomaras: HIV-1 vaccine humoral immunity, immune correlates and mechanistic insights

Georgia Tomaras: HIV-1 vaccine humoral immunity, immune correlates and mechanistic insights

Matthew Sutton: Importance of CD8 T cell responses targeting variable epitopes in SIV

Matthew Sutton: Importance of CD8 T cell responses targeting variable epitopes in SIV

Kshitij Wagh: Optimal combinations of bn-ab for prevention & therapy of HIV-1 Clade C infection

Kshitij Wagh: Optimal combinations of bn-ab for prevention & therapy of HIV-1 Clade C infection

Marit J van Gils: A broadly neutralizing antibody from an elite neutralizer

Marit J van Gils: A broadly neutralizing antibody from an elite neutralizer

Pamela Bjorkman: Structural studies of HIV-1 infection

Pamela Bjorkman: Structural studies of HIV-1 infection

Tomas Hanke: A novel conserved-region T-cell mosaic vaccine

Tomas Hanke: A novel conserved-region T-cell mosaic vaccine

Luca Micci: Determinants of viral control following ART-interruption in SIV-infected macaques

Luca Micci: Determinants of viral control following ART-interruption in SIV-infected macaques

Anthony Fauci: Ending the HIV/AIDS Pandemic: Follow the Science

Anthony Fauci: Ending the HIV/AIDS Pandemic: Follow the Science

MODULE #5: Product Development Partnerships (PDP's): Best Practices

MODULE #5: Product Development Partnerships (PDP's): Best Practices

MODULE #4: Planning for Success

MODULE #4: Planning for Success

MODULE #3: Moving vaccine concepts from bench-to-clinic

MODULE #3: Moving vaccine concepts from bench-to-clinic

MODULE #2: Target Product Profile (TPP)

MODULE #1: Pipeline and Portfolio Considerations

MODULE #1: Pipeline and Portfolio Considerations

Overview: Product Development Boot Camp

Overview: Product Development Boot Camp